The pharmaceutical group Krka reported that its sales revenue reached 1.6 billion euros during the first nine months of the year, marking an eight percent increase compared to the same period last year. Net profit rose by 13 percent to 364.2 million euros, while EBITDA increased by 21 percent to 527.9 million euros. Based on these interim results, the company expects total annual revenue to approach 2.2 billion euros and estimates net profit at 439 million euros. Management stated that these figures confirm the successful execution of their long-term strategy.
Bias read (Center): The article presents standard corporate financial metrics using neutral, factual language typical of business reporting, with no political framing or controversial elements.




